-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
- This cooperation aims to expand the opportunity of the new drug LYR-210 for the treatment of chronic sinusitis (CRS), benefiting more than 88 million adult patients with chronic sinusitis in China
Lyra Therapeutics, Inc.
(NASDAQ: LYRA) is a clinical-stage pharmaceutical company that focuses on using its exclusive XTreoTM platform for precise, continuous, and topical drug delivery to deliver drugs to the ear, nose, and throat (ENT) channels and Other diseased tissue areas
.
LianBio is a biopharmaceutical company focused on bringing disruptive drugs to patients in major markets in China and Asia
Under the terms of the agreement, Lyra will receive a down payment of US$12 million and is eligible for development, regulatory and commercialization milestone payments of up to US$135 million
.
After the commercialization starts, Lyra can also obtain a low double-digit tiered sales share based on the net sales of LYR-210 in each authorized region
"We are very pleased to enter into a strategic alliance with Liantuo Biotechnology to expand the global business scope of LYR-210 and replace surgery with innovative drug treatments to benefit millions of patients with chronic sinusitis,
" said Dr.
Maria Palasis, CEO of Lyra.
"Currently, patients with chronic sinusitis who have failed drug treatment can only control their disease through very limited invasive treatment options
.
" said Dr.
About LYR-210
LYR-210 is a product candidate developed on Lyra's unique XTreo™ platform.
It can provide chronic sinusitis patients with local anti-inflammatory treatment for up to 6 months through a single treatment
.
LYR-210 is a non-invasive alternative to sinus surgery designed for millions of patients with chronic sinusitis who have failed medical treatment
About Lyra Therapeutics
Lyra Therapeutics, Inc.
is a clinical-stage pharmaceutical company that focuses on using its exclusive XTreoTM platform to deliver drugs to ear, nose, and throat (ENT) channels and other pathologies that cannot be reached by traditional treatment methods with precise, continuous, and topical drug delivery.
Organization area
.
Lyra's XTreoTM platform consists of a biocompatible mesh stent, a modified elastic matrix and a multifunctional polymer drug complex
About Liantuo Bio
LianBio's mission is to provide the best scientific breakthrough therapy for patients in Greater China and other major Asian markets through efficient product development through a strategic partnership with the world's leading biopharmaceutical companies
.
By cooperating with world-class partners in different treatment fields and regions, Linktop has established a product pipeline based on disease relevance, and improved the patient's condition through transformation mechanisms and precision therapies
